Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00428
|
|||||
| Drug Name |
Prednisolone
|
|||||
| Synonyms |
Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Multiple scierosis [ICD11:8A40] | Approved | [1] | |||
| Adrenocortical insufficiency [ICD11:5A74] | Approved | [1] | ||||
| Rheumatoid arthritis [ICD11:FA20] | Approved | [1] | ||||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C21H28O5
|
|||||
| Canonical SMILES |
CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
|
|||||
| InChI |
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
|
|||||
| InChIKey |
OIGNJSKKLXVSLS-VWUMJDOOSA-N
|
|||||
| CAS Number |
CAS 50-24-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 360.4 | Topological Polar Surface Area | 94.8 | ||
| Heavy Atom Count | 26 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
1.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103189031
,10321429
,103913923
,104169971
,11466302
,11467422
,11486103
,12012573
,12146616
,14876794
,14876795
,24870351
,24898079
,24898725
,26697414
,29224791
,46504847
,46519223
,47500929
,47647896
,47945232
,48244811
,48414366
,48416460
,49698415
,49857644
,50085972
,50124371
,50643467
,53790825
,56311149
,56312886
,56313992
,56463372
,57288815
,57650843
,74674
,75254
,7847538
,7980377
,81093218
,8153532
,85300842
,85788424
,87574796
,92125114
,92309181
,92710510
,93576750
,9573
|
|||||
| ChEBI ID |
CHEBI:8378
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Prednisolone was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol. 2002 Oct;175(1):251-60. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.